Clinical trials for Indolent B-cell non-Hodgkin lymphoma
24 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center · PI: Sumithira Vasu, MD
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center · PI: Alexandre V. Hirayama, MD
- RECRUITINGPhase 1NCT06824701Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah · PI: Narendranath Epperla, MD, MS, FACP
- RECRUITINGPhase 2NCT07030699A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaMemorial Sloan Kettering Cancer Center · PI: Pallawi Torka, MD
- RECRUITINGPhase 3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center · PI: Brandon Imber, MD
- RECRUITINGPhase 2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine · PI: Elise Chong, MD
- RECRUITINGPhase 2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington · PI: Ajay Gopal
- RECRUITINGPhase 2NCT06386315Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin LymphomaMayo Clinic · PI: Bradford S. Hoppe, MD, MPH
- RECRUITINGPhase 2NCT06350318Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasH. Lee Moffitt Cancer Center and Research Institute · PI: Sameh Gaballa, MD
- RECRUITINGPhase 1NCT06209619CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaNathan Denlinger · PI: Nathan Denlinger, DO, MS
- ACTIVE NOT RECRUITINGPhase 2NCT05783596Glofit and Obin in Follicular Lymphoma and Marginal Zone LymphomaReid Merryman, MD · PI: Reid Merryman, MD
- RECRUITINGN/ANCT05876923The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PatientsMayo Clinic · PI: Michael P. Gustafson, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT05359211NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell LymphomaFred Hutchinson Cancer Center · PI: Alexandre Hirayama
- RECRUITINGPhase 2NCT04883437Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasEmory University · PI: Jonathon B Cohen, MD, MS
- ACTIVE NOT RECRUITINGPhase 1NCT04447716An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentThomas Jefferson University · PI: Ubaldo R Martinez-Outschoorn, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03884998Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaCity of Hope Medical Center · PI: Alexey V Danilov
- RECRUITINGPHASE1, PHASE2NCT03571568A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLBioInvent International AB
- ACTIVE NOT RECRUITINGPhase 2NCT03198026Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · PI: Ubaldo Martinez-Outschoorn, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03147885Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaBarbara Ann Karmanos Cancer Institute · PI: Dipenkumar Modi, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT02494700Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell LymphomaM.D. Anderson Cancer Center · PI: Chelsea C Pinnix, M D
- ACTIVE NOT RECRUITINGPhase 1NCT01479842Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaKami Maddocks, MD · PI: Kami Maddocks, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01318317Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin LymphomaCity of Hope Medical Center · PI: Elizabeth L Budde, MD,PhD
- ACTIVE NOT RECRUITINGPhase 3NCT00877214Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasJurgen Barth · PI: Mathias Rummel, Dr
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00466531Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19Memorial Sloan Kettering Cancer Center · PI: Jae Park, MD